Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.53 |
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21079315 | 0.87 | KMT2A (0.50) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL17014698 | 0.87 | HTT (0.46) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL8554478 | 0.86 | ALDH1A1 (0.52) | RXRARXRBRXRGKMT2ATSHR | |
| SCHEMBL13066210 | 0.86 | RXRA (0.64) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL9944064 | 0.85 | PKM (0.54) | RXRARXRBRXRGKMT2ATSHR | |
| SCHEMBL4695867 | 0.84 | CA12 (0.65) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3545163 | 0.84 | KMT2A (0.58) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL22343539 | 0.82 | RXRA (0.41) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL9005609 | 0.81 | TTR (0.56) | RXRARXRBRXRGKMT2ACA12 | |
| SCHEMBL2543398 | 0.81 | KMT2A (0.55) | RXRARXRBRXRGKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767281-B2 | Manufacturing and purification technology for high purity Propofol | Chodankar Nandkumar Kashinath (IN) | 2023-09-26 | — | — | US | disclosed |
| US-11767281-B2 | Manufacturing and purification technology for high purity Propofol | Chodankar Nandkumar Kashinath (IN) | 2023-09-26 | — | — | US | disclosed |
| US-20230159420-A1 | MANUFACTURING AND PURIFICATION TECHNOLOGY FOR HIGH PURITY PROPOFOL | Chodankar Nandkumar Kashinath (IN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159420-A1 | MANUFACTURING AND PURIFICATION TECHNOLOGY FOR HIGH PURITY PROPOFOL | Chodankar Nandkumar Kashinath (IN) | 2023-05-25 | — | — | US | disclosed |
| US-5767146-A | Anti-osteopathic composition | HOECHST JAPAN LIMITED (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5716995-A | TREATING OR PREVENTING BONE DISEASES BY ADMINISTERING PHENOLIC, HETERO- OR NAPHTHYL- DERIVATIVES OF 1-HYDROXY-3-OXO-1-PROPENYL BENZOIC ACID TO PROMOTE OSTEOGENESIS | HOECHST JAPAN LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5703128-A | TREATING OSTEOPOROSIS, BONE FRACTURES | HOECHST JAPAN LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5525618-A | ENHANCING OSTEOGENESIS, PREVENTING OSTEOPOROSIS | HOECHST JAPAN LIMITED (JP) | 1996-06-11 | — | — | US | disclosed |
| EP-0619116-A2 | Use of synthetic retinoids for osteopathy | HOECHST JAPAN LIMITED (JP) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159420-A1 | MANUFACTURING AND PURIFICATION TECHNOLOGY FOR HIGH PURITY PROPOFOL | MGMT, SUZ12, U2AF1 | RXRA 2243/4885RXRB 2634/4885RXRG 2042/4885 |
| US-11767281-B2 | Manufacturing and purification technology for high purity Propofol | MGMT, SUZ12, U2AF1 | RXRA 2243/4885RXRB 2634/4885RXRG 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.